Xeomin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Xeomin comprises 141 peer-reviewed publications across 15 journals, 19 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Urinary Incontinence, Brain Injuries, Traumatic, Muscle Spasticity, and Erectile Dysfunction. Most recent publication: Effects of 3 Cycles of Increasing Botulinum Toxin Doses on Functional Parameters of Post-stroke Spastic Gait: A Prospective Cohort Study., NeuroRehabilitation, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. The management of neurogenic lower urinary tract dysfunction after spinal cord injury.
    Wyndaele JJ · Nat Rev Urol · 2018
    PubMed: PMID 27779229 · NCT03758235 · Urinary Incontinence
  2. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
    Wang L, Sun Y, Yang W, et al. · Toxicon · 2014
    PubMed: PMID 24560879 · NCT03758235 · Urinary Incontinence
  3. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R, Harding C, Teo L, et al. · Int J Urol · 2014
    PubMed: PMID 23819724 · NCT03758235 · Urinary Incontinence
  4. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH, Benecke R, Hauschke D, et al. · Drug Des Devel Ther · 2016
    PubMed: PMID 25897202 · NCT03758235 · Urinary Incontinence
  5. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.
    Gormley EA, Lightner DJ, Faraday M, et al. · J Urol · 2015
    PubMed: PMID 25623739 · NCT03758235 · Urinary Incontinence
  6. Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products.
    Frevert J · Drugs R D · 2015
    PubMed: PMID 25851380 · NCT03758235 · Urinary Incontinence
  7. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
    Comella C, Hauser RA, Isaacson SH, et al. · Clin Park Relat Disord · 2022
    PubMed: PMID 35330880 · NCT01486264 · Torticollis
  8. Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.
    Aharony SM, Lam O, Corcos J, et al. · Can Urol Assoc J · 2020
    PubMed: PMID 28443147 · NCT03758235 · Urinary Incontinence

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00406367BlepharospasmJankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater)
Baseline, week 6
incobotulinumtoxinA (Xeomin)-0.8 Points on a scale (±0.13 Standard Error)
Placebo0.2 Points on a scale (±0.18 Standard Error)
NCT00407030TorticollisChange From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (120 Units) Versus Placebo
Baseline, week 4
incobotulinumtoxinA (Xeomin) (120 Units)-10.8 points on a scale (±2.11 Standard Error)
Placebo-3.3 points on a scale (±2.20 Standard Error)
NCT00407030TorticollisChange From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo
Baseline, week 4
incobotulinumtoxinA (Xeomin) (240 Units)-7.3 points on a scale (±2.18 Standard Error)
Placebo1.6 points on a scale (±2.28 Standard Error)
NCT00407030TorticollisChange From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Xeomin (120 Units)
Baseline, week 4
incobotulinumtoxinA (Xeomin) (120 Units)-9.2 points on a scale (±2.27 Standard Error)
incobotulinumtoxinA (Xeomin) (240 Units)-10.5 points on a scale (±2.25 Standard Error)
NCT00432666—Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors
Baseline, Week 4
incobotulinumtoxinA (Xeomin)50 Participants
Placebo28 Participants
NCT00465738
NT-Spin
—Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set
At week 4
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL51 participants
incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL44 participants
NCT00512135—Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at Maximum Frown
At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U19 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U44 Participants
IncobotulinumtoxinA 20 U95 Participants
IncobotulinumtoxinA 20 U64 Participants
IncobotulinumtoxinA 20 U39 Participants
IncobotulinumtoxinA 20 U14 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U25 Participants
IncobotulinumtoxinA 20 U49 Participants
IncobotulinumtoxinA 20 U32 Participants
IncobotulinumtoxinA 20 U9 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U22 Participants
IncobotulinumtoxinA 20 U14 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U28 Participants
IncobotulinumtoxinA 20 U99 Participants
IncobotulinumtoxinA 20 U223 Participants
IncobotulinumtoxinA 20 U259 Participants
IncobotulinumtoxinA 20 U162 Participants
IncobotulinumtoxinA 20 U9 Participants
IncobotulinumtoxinA 20 U54 Participants
IncobotulinumtoxinA 20 U97 Participants
IncobotulinumtoxinA 20 U208 Participants
IncobotulinumtoxinA 20 U208 Participants
IncobotulinumtoxinA 20 U105 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U49 Participants
IncobotulinumtoxinA 20 U100 Participants
IncobotulinumtoxinA 20 U114 Participants
IncobotulinumtoxinA 20 U44 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U14 Participants
IncobotulinumtoxinA 20 U41 Participants
IncobotulinumtoxinA 20 U104 Participants
IncobotulinumtoxinA 20 U90 Participants
IncobotulinumtoxinA 20 U55 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U16 Participants
IncobotulinumtoxinA 20 U55 Participants
IncobotulinumtoxinA 20 U89 Participants
IncobotulinumtoxinA 20 U81 Participants
IncobotulinumtoxinA 20 U45 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U16 Participants
IncobotulinumtoxinA 20 U52 Participants
IncobotulinumtoxinA 20 U73 Participants
IncobotulinumtoxinA 20 U83 Participants
IncobotulinumtoxinA 20 U31 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U16 Participants
IncobotulinumtoxinA 20 U51 Participants
IncobotulinumtoxinA 20 U52 Participants
IncobotulinumtoxinA 20 U17 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U14 Participants
IncobotulinumtoxinA 20 U13 Participants
IncobotulinumtoxinA 20 U13 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U118 Participants
IncobotulinumtoxinA 20 U74 Participants
IncobotulinumtoxinA 20 U50 Participants
IncobotulinumtoxinA 20 U256 Participants
IncobotulinumtoxinA 20 U210 Participants
IncobotulinumtoxinA 20 U140 Participants
IncobotulinumtoxinA 20 U46 Participants
IncobotulinumtoxinA 20 U16 Participants
IncobotulinumtoxinA 20 U99 Participants
IncobotulinumtoxinA 20 U228 Participants
IncobotulinumtoxinA 20 U187 Participants
IncobotulinumtoxinA 20 U114 Participants
IncobotulinumtoxinA 20 U39 Participants
IncobotulinumtoxinA 20 U23 Participants
IncobotulinumtoxinA 20 U52 Participants
IncobotulinumtoxinA 20 U113 Participants
IncobotulinumtoxinA 20 U84 Participants
IncobotulinumtoxinA 20 U44 Participants
IncobotulinumtoxinA 20 U19 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U57 Participants
IncobotulinumtoxinA 20 U96 Participants
IncobotulinumtoxinA 20 U83 Participants
IncobotulinumtoxinA 20 U49 Participants
IncobotulinumtoxinA 20 U16 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U51 Participants
IncobotulinumtoxinA 20 U98 Participants
IncobotulinumtoxinA 20 U84 Participants
IncobotulinumtoxinA 20 U35 Participants
NCT00512135—Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at Rest
At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U163 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U34 Participants
IncobotulinumtoxinA 20 U53 Participants
IncobotulinumtoxinA 20 U90 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U29 Participants
IncobotulinumtoxinA 20 U72 Participants
IncobotulinumtoxinA 20 U111 Participants
IncobotulinumtoxinA 20 U98 Participants
IncobotulinumtoxinA 20 U12 Participants
IncobotulinumtoxinA 20 U15 Participants
IncobotulinumtoxinA 20 U57 Participants
IncobotulinumtoxinA 20 U205 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U28 Participants
IncobotulinumtoxinA 20 U89 Participants
IncobotulinumtoxinA 20 U144 Participants
IncobotulinumtoxinA 20 U281 Participants
IncobotulinumtoxinA 20 U237 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U24 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U24 Participants
IncobotulinumtoxinA 20 U54 Participants
IncobotulinumtoxinA 20 U64 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U27 Participants
IncobotulinumtoxinA 20 U12 Participants
IncobotulinumtoxinA 20 U33 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U20 Participants
IncobotulinumtoxinA 20 U35 Participants
IncobotulinumtoxinA 20 U90 Participants
IncobotulinumtoxinA 20 U73 Participants
IncobotulinumtoxinA 20 U34 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U25 Participants
IncobotulinumtoxinA 20 U55 Participants
IncobotulinumtoxinA 20 U96 Participants
IncobotulinumtoxinA 20 U71 Participants
IncobotulinumtoxinA 20 U33 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U30 Participants
IncobotulinumtoxinA 20 U65 Participants
IncobotulinumtoxinA 20 U82 Participants
IncobotulinumtoxinA 20 U88 Participants
IncobotulinumtoxinA 20 U32 Participants
IncobotulinumtoxinA 20 U12 Participants
IncobotulinumtoxinA 20 U24 Participants
IncobotulinumtoxinA 20 U81 Participants
IncobotulinumtoxinA 20 U88 Participants
IncobotulinumtoxinA 20 U81 Participants
IncobotulinumtoxinA 20 U31 Participants
IncobotulinumtoxinA 20 U19 Participants
IncobotulinumtoxinA 20 U50 Participants
IncobotulinumtoxinA 20 U125 Participants
IncobotulinumtoxinA 20 U190 Participants
IncobotulinumtoxinA 20 U199 Participants
IncobotulinumtoxinA 20 U98 Participants
IncobotulinumtoxinA 20 U28 Participants
IncobotulinumtoxinA 20 U25 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U80 Participants
IncobotulinumtoxinA 20 U102 Participants
IncobotulinumtoxinA 20 U55 Participants
IncobotulinumtoxinA 20 U13 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U76 Participants
IncobotulinumtoxinA 20 U37 Participants
IncobotulinumtoxinA 20 U12 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U251 Participants
IncobotulinumtoxinA 20 U150 Participants
IncobotulinumtoxinA 20 U123 Participants
IncobotulinumtoxinA 20 U92 Participants
IncobotulinumtoxinA 20 U59 Participants
IncobotulinumtoxinA 20 U111 Participants
IncobotulinumtoxinA 20 U52 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U70 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U204 Participants
IncobotulinumtoxinA 20 U241 Participants
IncobotulinumtoxinA 20 U71 Participants
NCT00512135—Incidence of Adverse Events (AEs)
Baseline up to Month 30
IncobotulinumtoxinA 20 U374 Participants
NCT00512135—Incidence of Adverse Events of Special Interest (AESI)
Baseline up to Month 30
IncobotulinumtoxinA 20 U9 Participants
NCT00512135—Percentage of Responders at Maximum Frown as Assessed by the Investigator According to Facial Wrinkle Scale (FWS)
At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U81.4 percentage of participants
IncobotulinumtoxinA 20 U80.3 percentage of participants
IncobotulinumtoxinA 20 U80.1 percentage of participants
IncobotulinumtoxinA 20 U79.8 percentage of participants
IncobotulinumtoxinA 20 U79.1 percentage of participants
IncobotulinumtoxinA 20 U17.8 percentage of participants
IncobotulinumtoxinA 20 U8.8 percentage of participants
IncobotulinumtoxinA 20 U4.8 percentage of participants
IncobotulinumtoxinA 20 U0.6 percentage of participants
IncobotulinumtoxinA 20 U6.5 percentage of participants
IncobotulinumtoxinA 20 U89.6 percentage of participants
IncobotulinumtoxinA 20 U29.2 percentage of participants
IncobotulinumtoxinA 20 U0.6 percentage of participants
IncobotulinumtoxinA 20 U16.6 percentage of participants
IncobotulinumtoxinA 20 U81.2 percentage of participants
IncobotulinumtoxinA 20 U82.7 percentage of participants
NCT00512135—Percentage of Responders at Maximum Frown by Participant's Assessment on the 4-point Scale
At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U90.1 percentage of participants
IncobotulinumtoxinA 20 U52.4 percentage of participants
IncobotulinumtoxinA 20 U41.8 percentage of participants
IncobotulinumtoxinA 20 U43.6 percentage of participants
IncobotulinumtoxinA 20 U38.2 percentage of participants
IncobotulinumtoxinA 20 U43.8 percentage of participants
IncobotulinumtoxinA 20 U31.2 percentage of participants
IncobotulinumtoxinA 20 U93.8 percentage of participants
IncobotulinumtoxinA 20 U60.4 percentage of participants
IncobotulinumtoxinA 20 U88.5 percentage of participants
IncobotulinumtoxinA 20 U85.9 percentage of participants
IncobotulinumtoxinA 20 U87.4 percentage of participants
IncobotulinumtoxinA 20 U88.2 percentage of participants
IncobotulinumtoxinA 20 U86.2 percentage of participants
IncobotulinumtoxinA 20 U37.9 percentage of participants
IncobotulinumtoxinA 20 U87.6 percentage of participants
NCT00512135—Percentage of Responders at Rest as Assessed by the Investigator According to FWS
At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U57.0 percentage of participants
IncobotulinumtoxinA 20 U87.5 percentage of participants
IncobotulinumtoxinA 20 U81.2 percentage of participants
IncobotulinumtoxinA 20 U77.0 percentage of participants
IncobotulinumtoxinA 20 U79.4 percentage of participants
IncobotulinumtoxinA 20 U80.6 percentage of participants
IncobotulinumtoxinA 20 U80.7 percentage of participants
IncobotulinumtoxinA 20 U79.7 percentage of participants
IncobotulinumtoxinA 20 U78.9 percentage of participants
IncobotulinumtoxinA 20 U67.0 percentage of participants
IncobotulinumtoxinA 20 U64.4 percentage of participants
IncobotulinumtoxinA 20 U63.2 percentage of participants
IncobotulinumtoxinA 20 U60.5 percentage of participants
IncobotulinumtoxinA 20 U63.7 percentage of participants
IncobotulinumtoxinA 20 U83.3 percentage of participants
IncobotulinumtoxinA 20 U63.8 percentage of participants
NCT00512135—Percentage of Responders at Rest by Participant's Assessment on the 4-point Scale
At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U58.3 percentage of participants
IncobotulinumtoxinA 20 U49.0 percentage of participants
IncobotulinumtoxinA 20 U43.6 percentage of participants
IncobotulinumtoxinA 20 U42.1 percentage of participants
IncobotulinumtoxinA 20 U38.8 percentage of participants
IncobotulinumtoxinA 20 U77.1 percentage of participants
IncobotulinumtoxinA 20 U75.9 percentage of participants
IncobotulinumtoxinA 20 U75.1 percentage of participants
IncobotulinumtoxinA 20 U73.0 percentage of participants
IncobotulinumtoxinA 20 U67.0 percentage of participants
IncobotulinumtoxinA 20 U69.5 percentage of participants
IncobotulinumtoxinA 20 U43.2 percentage of participants
IncobotulinumtoxinA 20 U35.1 percentage of participants
IncobotulinumtoxinA 20 U73.8 percentage of participants
IncobotulinumtoxinA 20 U77.0 percentage of participants
IncobotulinumtoxinA 20 U54.5 percentage of participants
NCT00512135—Time to Onset of Treatment Effect
From injection visit up to date of onset of treatment effect in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
IncobotulinumtoxinA 20 U21 Participants
IncobotulinumtoxinA 20 U17 Participants
IncobotulinumtoxinA 20 U20 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U11 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U33 Participants
IncobotulinumtoxinA 20 U46 Participants
IncobotulinumtoxinA 20 U56 Participants
IncobotulinumtoxinA 20 U42 Participants
IncobotulinumtoxinA 20 U20 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U21 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U15 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U8 Participants
IncobotulinumtoxinA 20 U17 Participants
IncobotulinumtoxinA 20 U36 Participants
IncobotulinumtoxinA 20 U43 Participants
IncobotulinumtoxinA 20 U29 Participants
IncobotulinumtoxinA 20 U19 Participants
IncobotulinumtoxinA 20 U8 Participants
IncobotulinumtoxinA 20 U15 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U2 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U0 Participants
IncobotulinumtoxinA 20 U1 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U17 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U7 Participants
IncobotulinumtoxinA 20 U15 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U86 Participants
IncobotulinumtoxinA 20 U168 Participants
IncobotulinumtoxinA 20 U171 Participants
IncobotulinumtoxinA 20 U93 Participants
IncobotulinumtoxinA 20 U75 Participants
IncobotulinumtoxinA 20 U33 Participants
IncobotulinumtoxinA 20 U70 Participants
IncobotulinumtoxinA 20 U12 Participants
IncobotulinumtoxinA 20 U5 Participants
IncobotulinumtoxinA 20 U48 Participants
IncobotulinumtoxinA 20 U20 Participants
IncobotulinumtoxinA 20 U22 Participants
IncobotulinumtoxinA 20 U106 Participants
IncobotulinumtoxinA 20 U134 Participants
IncobotulinumtoxinA 20 U138 Participants
IncobotulinumtoxinA 20 U82 Participants
IncobotulinumtoxinA 20 U53 Participants
IncobotulinumtoxinA 20 U17 Participants
IncobotulinumtoxinA 20 U58 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U9 Participants
IncobotulinumtoxinA 20 U41 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U8 Participants
IncobotulinumtoxinA 20 U44 Participants
IncobotulinumtoxinA 20 U56 Participants
IncobotulinumtoxinA 20 U70 Participants
IncobotulinumtoxinA 20 U46 Participants
IncobotulinumtoxinA 20 U36 Participants
IncobotulinumtoxinA 20 U11 Participants
IncobotulinumtoxinA 20 U18 Participants
IncobotulinumtoxinA 20 U3 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U15 Participants
IncobotulinumtoxinA 20 U4 Participants
IncobotulinumtoxinA 20 U10 Participants
IncobotulinumtoxinA 20 U39 Participants
IncobotulinumtoxinA 20 U54 Participants
IncobotulinumtoxinA 20 U78 Participants
IncobotulinumtoxinA 20 U33 Participants
IncobotulinumtoxinA 20 U29 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U22 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U18 Participants
IncobotulinumtoxinA 20 U6 Participants
IncobotulinumtoxinA 20 U9 Participants
IncobotulinumtoxinA 20 U37 Participants
IncobotulinumtoxinA 20 U64 Participants
IncobotulinumtoxinA 20 U57 Participants
IncobotulinumtoxinA 20 U39 Participants
NCT00770029—Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's Rating on Facial Wrinkle Scale (FWS) and by Patient's Assessment on 4-point Scale
Baseline to Day 30
IncobotulinumtoxinA (Xeomin) (20 Units)111 Participants
Placebo0 Participants
NCT00770211—Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's Rating on the Facial Wrinkle Scale and the Patient's Assessment on 4-point Scale
Baseline to Day 30
IncobotulinumtoxinA (Xeomin) (20 Units)87 Particpants
Placebo0 Particpants
NCT00777803
Head2Head
—Responder by Independent Rater's Assessment at Maximum Frown at Week 4
4 weeks after injection
IncobotulinumtoxinA (Xeomin®/Bocouture®)267 participants
OnabotulinumtoxinA (Vistabel®)89 participants
NCT01896895—Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4)
Baseline, Day 43 (Visit 4)
Double-blind MP: IncobotulinumtoxinA 25 Units-1.0 score on a scale
Double-blind MP: IncobotulinumtoxinA 50 Units-1.8 score on a scale
Double-blind MP: Placebo-0.6 score on a scale

Publications by year

1983–2025: 141 publications.

1983
1
1984
1
1986
1
1988
1
1992
1
1994
2
1995
2
1996
1
1997
1
1998
1
1999
1
2000
2
2001
3
2002
1
2003
1
2004
4
2005
5
2006
4
2007
4
2008
4
2009
6
2010
6
2011
5
2012
12
2013
8
2014
15
2015
7
2016
9
2017
4
2018
7
2019
2
2020
4
2021
4
2022
4
2023
2
2024
3
2025
2

Publications by indication

Urinary Incontinence (20)

  • Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.
    Can Urol Assoc J · 2020 · PMID 28443147 · NCT03758235
  • The management of neurogenic lower urinary tract dysfunction after spinal cord injury.
    Nat Rev Urol · 2018 · PMID 27779229 · NCT03758235
  • Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Drug Des Devel Ther · 2016 · PMID 25897202 · NCT03758235
  • Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.
    J Urol · 2015 · PMID 25623739 · NCT03758235
  • Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products.
    Drugs R D · 2015 · PMID 25851380 · NCT03758235

Brain Injuries, Traumatic (16)

  • Neuroimaging Findings in US Government Personnel and Their Family Members Involved in Anomalous Health Incidents.
    JAMA · 2024 · PMID 38497822 · NCT07267819
  • Identifying Migraine Phenotype Post Traumatic Headache (MPTH) to Guide Overall Recovery From Traumatic Brain Injury.
    J Child Neurol · 2024 · PMID 35656769 · NCT07267819
  • A regulatory pathway model of neuropsychological disruption in Havana syndrome.
    Front Psychiatry · 2024 · PMID 37965360 · NCT07267819
  • Havana syndrome: a scoping review of the existing literature.
    Rev Environ Health · 2023 · PMID 35962646 · NCT07267819
  • Symptoms reported by Canadians posted in Havana are linked with reduced white matter fibre density.
    Brain Commun · 2022 · PMID 35505689 · NCT07267819

Muscle Spasticity (10)

  • Effects of 3 Cycles of Increasing Botulinum Toxin Doses on Functional Parameters of Post-stroke Spastic Gait: A Prospective Cohort Study.
    NeuroRehabilitation · 2025 · PMID 40135684 · NCT04544280
  • Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.
    Neurology · 2017 · PMID 28283596 · NCT04544280
  • Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections.
    Muscle Nerve · 2015 · PMID 25598004 · NCT04544280
  • The reasons why stroke patients expend so much energy to walk slowly.
    Gait Posture · 2013 · PMID 22555062 · NCT04544280
  • Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait.
    Stroke · 2008 · PMID 18635841 · NCT04544280

Erectile Dysfunction (4)

  • Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors.
    J Sex Med · 2025 · PMID 40971935 · NCT05196308
  • Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series.
    Toxins (Basel) · 2022 · PMID 35448895 · NCT05196308
  • Standards for Clinical Trials in Male and Female Sexual Dysfunction: III. Unique Aspects of Clinical Trials in Male Sexual Dysfunction.
    J Sex Med · 2017 · PMID 28065358 · NCT05196308
  • Validation of the erection hardness score.
    J Sex Med · 2008 · PMID 17888069 · NCT05196308

Torticollis (3)

  • Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
    Clin Park Relat Disord · 2022 · PMID 35330880 · NCT01486264
  • A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
    J Neural Transm (Vienna) · 2014 · PMID 23779062 · NCT00407030
  • Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    J Neurol Sci · 2012 · PMID 21764407 · NCT00407030

Sleep Bruxism (3)

  • Reliability of a two-colour chewing gum test to assess masticatory performance in complete denture wearers.
    J Oral Rehabil · 2018 · PMID 29356092 · NCT04792398
  • A pilot study of ambulatory masticatory muscle activities in temporomandibular joint disorders diagnostic groups.
    Orthod Craniofac Res · 2016 · PMID 25865543 · NCT04792398
  • Design, construction, and technical implementation of a web-based interdisciplinary symptom evaluation (WISE) - a heuristic proposal for orofacial pain and temporomandibular disorders.
    J Headache Pain · 2016 · PMID 27581159 · NCT04792398

Publications by journal

Trial-results highlights

In a study of blepharospasm, NCT00406367, the Jankovic Rating Scale (JRS) Severity Subscore at Week 6 after injection showed a change from baseline of -0.8 Points for the incobotulinumtoxinA (Xeomin) arm, compared to 0.2 Points for the placebo arm. For cervical dystonia (torticollis), the NCT00407030 study evaluated the change from baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4. In this study, the incobotulinumtoxinA (Xeomin) 120 Units arm showed a change of -10.8 points, while the placebo arm showed a change of -3.3 points. The incobotulinumtoxinA (Xeomin) 240 Units arm showed a change of -7.3 points, compared to 1.6 points for the placebo arm. When comparing different doses of incobotulinumtoxinA (Xeomin) in NCT00407030, the 120 Units arm showed a change of -9.2 points, and the 240 Units arm showed a change of -10.5 points.

In a study focusing on spasticity, NCT00432666, the number of participants with a reduction of at least 1 point in the Ashworth Score in wrist flexors at Week 4 compared to baseline was 50 Participants in the incobotulinumtoxinA (Xeomin) arm, versus 28 Participants in the placebo arm. Another study, NCT00465738 (NT-Spin), assessed responders in the Disability Assessment Scale (DAS) at Week 4. In this trial, the incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL arm had 51 participants who were responders, and the incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL arm had 44 participants who were responders.

For glabellar lines, the NCT00512135 study reported participant assessments on a 6-point Likert Type Scale. For glabellar lines at maximum frown, the number of participants for incobotulinumtoxinA 20 U were:

  • 19 Participants
  • 3 Participants
  • 44 Participants
  • 95 Participants
  • 64 Participants
  • 39 Participants

For glabellar lines at rest, the number of participants for incobotulinumtoxinA 20 U were:

  • 163 Participants
  • 3 Participants
  • 2 Participants
  • 34 Participants
  • 53 Participants
  • 90 Participants

All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Xeomin publications (141)

2025 (2 papers)

  1. Effects of 3 Cycles of Increasing Botulinum Toxin Doses on Functional Parameters of Post-stroke Spastic Gait: A Prospective Cohort Study.
    Selves C, Dehem S, Lejeune T, et al. · NeuroRehabilitation · 2025 · Derived
    PubMed: PMID 40135684 · NCT04544280 · Muscle Spasticity
  2. Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors.
    Giuliano F, Denormandie AC, Madec FX, et al. · J Sex Med · 2025 · Derived
    PubMed: PMID 40971935 · NCT05196308 (MENOX) · Erectile Dysfunction

2024 (3 papers)

  1. Neuroimaging Findings in US Government Personnel and Their Family Members Involved in Anomalous Health Incidents.
    Pierpaoli C, Nayak A, Hafiz R, et al. · JAMA · 2024 · Background
    PubMed: PMID 38497822 · NCT07267819 · Brain Injuries, Traumatic
  2. Identifying Migraine Phenotype Post Traumatic Headache (MPTH) to Guide Overall Recovery From Traumatic Brain Injury.
    Klein SK, Brown CB, Ostrowski-Delahanty S, et al. · J Child Neurol · 2024 · Background
    PubMed: PMID 35656769 · NCT07267819 · Brain Injuries, Traumatic
  3. A regulatory pathway model of neuropsychological disruption in Havana syndrome.
    Chacko TP, Toole JT, Morris MC, et al. · Front Psychiatry · 2024 · Background
    PubMed: PMID 37965360 · NCT07267819 · Brain Injuries, Traumatic

2023 (2 papers)

  1. A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine.
    Wilderman I, Tallarigo D, Pugacheva-Zingerman O, et al. · Pain Ther · 2023 · Background
    PubMed: PMID 34523107 · NCT05598723
  2. Havana syndrome: a scoping review of the existing literature.
    Asadi-Pooya AA · Rev Environ Health · 2023 · Background
    PubMed: PMID 35962646 · NCT07267819 · Brain Injuries, Traumatic

2022 (4 papers)

  1. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
    Comella C, Hauser RA, Isaacson SH, et al. · Clin Park Relat Disord · 2022 · Trial result
    PubMed: PMID 35330880 · NCT01486264 · Torticollis
  2. Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series.
    Giuliano F, Denys P, Joussain C, et al. · Toxins (Basel) · 2022 · Derived
    PubMed: PMID 35448895 · NCT05196308 (MENOX) · Erectile Dysfunction
  3. GLIMMPSE: Online Power Computation for Linear Models with and without a Baseline Covariate.
    Kreidler SM, Muller KE, Grunwald GK, et al. · J Stat Softw · 2022 · Background
    PubMed: PMID 24403868 · NCT05598723
  4. Symptoms reported by Canadians posted in Havana are linked with reduced white matter fibre density.
    Aristi G, Kamintsky L, Ross M, et al. · Brain Commun · 2022 · Background
    PubMed: PMID 35505689 · NCT07267819 · Brain Injuries, Traumatic

2021 (4 papers)

  1. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD, Dekundy A, Sternberg K, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 32779096 · NCT01896895
  2. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD, Dekundy A, Hanschmann A, et al. · Curr Med Res Opin · 2021 · Derived
    PubMed: PMID 34384301 · NCT01896895
  3. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK, Shah N, Poon JL, et al. · Headache · 2021 · Background
    PubMed: PMID 33594686 · NCT05598723
  4. Clinical Perspectives on Headache After Traumatic Brain Injury.
    Hoffman JM, Lucas S, Dikmen S, et al. · PM R · 2021 · Background
    PubMed: PMID 32003524 · NCT07267819 · Brain Injuries, Traumatic

2020 (4 papers)

  1. Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.
    Aharony SM, Lam O, Corcos J, et al. · Can Urol Assoc J · 2020 · Trial result
    PubMed: PMID 28443147 · NCT03758235 · Urinary Incontinence
  2. Botulinum toxin type A therapy for blepharospasm.
    Duarte GS, Rodrigues FB, Marques RE, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33211907 · NCT01896895
  3. Government Employees and Their Families at Overseas Embassies; Pavlin JA, Relman DA, editors
    · 2020 · Background
    PubMed: PMID 33411434 · NCT07267819 · Brain Injuries, Traumatic
  4. Post-traumatic headache: epidemiology and pathophysiological insights.
    Ashina H, Porreca F, Anderson T, et al. · Nat Rev Neurol · 2020 · Background
    PubMed: PMID 31527806 · NCT07267819 · Brain Injuries, Traumatic

2019 (2 papers)

  1. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, et al. · J Headache Pain · 2019 · Background
    PubMed: PMID 31307383 · NCT05598723
  2. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine.
    Ion I, Renard D, Le Floch A, et al. · Toxins (Basel) · 2019 · Background
    PubMed: PMID 29857565 · NCT05598723

2018 (7 papers)

  1. The management of neurogenic lower urinary tract dysfunction after spinal cord injury.
    Wyndaele JJ · Nat Rev Urol · 2018 · Trial result
    PubMed: PMID 27779229 · NCT03758235 · Urinary Incontinence
  2. Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba.
    Swanson RL, Hampton S, Green-McKenzie J, et al. · JAMA · 2018 · Background
    PubMed: PMID 29450484 · NCT07267819 · Brain Injuries, Traumatic
  3. Reliability of a two-colour chewing gum test to assess masticatory performance in complete denture wearers.
    Silva LC, Nogueira TE, Rios LF, et al. · J Oral Rehabil · 2018 · Background
    PubMed: PMID 29356092 · NCT04792398 (BRUX-XIT) · Sleep Bruxism
  4. Botulinum Toxin for the Treatment of Neuropathic Pain.
    Park J, Park HJ · Toxins (Basel) · 2018 · Background
    PubMed: PMID 28837075 · NCT03571334
  5. Chronic migraine: risk factors, mechanisms and treatment.
    May A, Schulte LH · Nat Rev Neurol · 2018 · Background
    PubMed: PMID 27389092 · NCT05598723
  6. Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain.
    Fan C, Chu X, Wang L, et al. · Toxicon · 2018 · Background
    PubMed: PMID 28478059 · NCT03571334
  7. Botulinum toxin: A review of the mode of action in migraine.
    Do TP, Hvedstrup J, Schytz HW, et al. · Acta Neurol Scand · 2018 · Background
    PubMed: PMID 29405250 · NCT05598723

2017 (4 papers)

  1. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.
    Wissel J, Bensmail D, Ferreira JJ, et al. · Neurology · 2017 · Background
    PubMed: PMID 28283596 · NCT04544280 · Muscle Spasticity
  2. The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon.
    Segreto F, Marangi GF, Cerbone V, et al. · Ann Plast Surg · 2017 · Background
    PubMed: PMID 26808752 · NCT03571334
  3. Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.
    Sandrini G, De Icco R, Tassorelli C, et al. · J Headache Pain · 2017 · Background
    PubMed: PMID 28324318 · NCT05598723
  4. Standards for Clinical Trials in Male and Female Sexual Dysfunction: III. Unique Aspects of Clinical Trials in Male Sexual Dysfunction.
    Fisher WA, Gruenwald I, Jannini EA, et al. · J Sex Med · 2017 · Background
    PubMed: PMID 28065358 · NCT05196308 (MENOX) · Erectile Dysfunction

2016 (9 papers)

  1. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH, Benecke R, Hauschke D, et al. · Drug Des Devel Ther · 2016 · Trial result
    PubMed: PMID 25897202 · NCT03758235 · Urinary Incontinence
  2. Pathophysiological links between traumatic brain injury and post-traumatic headaches.
    Ruff RL, Blake K · F1000Res · 2016 · Background
    PubMed: PMID 27635228 · NCT07267819 · Brain Injuries, Traumatic
  3. Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.
    Rostami R, Mittal SO, Radmand R, et al. · Toxins (Basel) · 2016 · Background
    PubMed: PMID 26771640 · NCT03571334
  4. Manual therapy and exercise for rotator cuff disease.
    Page MJ, Green S, McBain B, et al. · Cochrane Database Syst Rev · 2016 · Background
    PubMed: PMID 27283590 · NCT05327972 (DEROTOX)
  5. Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis.
    Lakhan SE, Velasco DN, Tepper D, et al. · Pain Med · 2016 · Background
    PubMed: PMID 25800040 · NCT03571334
  6. A pilot study of ambulatory masticatory muscle activities in temporomandibular joint disorders diagnostic groups.
    Iwasaki LR, Gonzalez YM, Liu H, et al. · Orthod Craniofac Res · 2016 · Background
    PubMed: PMID 25865543 · NCT04792398 (BRUX-XIT) · Sleep Bruxism
  7. Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin.
    Freeman R, Wallace MS, Sweeney M, et al. · Pain Med · 2016 · Background
    PubMed: PMID 26115203 · NCT03571334
  8. Design, construction, and technical implementation of a web-based interdisciplinary symptom evaluation (WISE) - a heuristic proposal for orofacial pain and temporomandibular disorders.
    Ettlin DA, Sommer I, Brönnimann B, et al. · J Headache Pain · 2016 · Background
    PubMed: PMID 27581159 · NCT04792398 (BRUX-XIT) · Sleep Bruxism
  9. Acute Migraine Treatment.
    Becker WJ · Continuum (Minneap Minn) · 2016 · Background
    PubMed: PMID 26252584 · NCT07267819 · Brain Injuries, Traumatic

2015 (7 papers)

  1. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.
    Gormley EA, Lightner DJ, Faraday M, et al. · J Urol · 2015 · Trial result
    PubMed: PMID 25623739 · NCT03758235 · Urinary Incontinence
  2. Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products.
    Frevert J · Drugs R D · 2015 · Trial result
    PubMed: PMID 25851380 · NCT03758235 · Urinary Incontinence
  3. A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles.
    Yeilding RH, Fezza JP · Plast Reconstr Surg · 2015 · Derived
    PubMed: PMID 25919246 · NCT02122536
  4. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin.
    Yiannakopoulou E · Pharmacology · 2015 · Background
    PubMed: PMID 25613637 · NCT05598723
  5. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
    Seretny M, Currie GL, Sena ES, et al. · Pain · 2015 · Background
    PubMed: PMID 25261162 · NCT03571334
  6. Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections.
    Minamoto VB, Suzuki KP, Bremner SN, et al. · Muscle Nerve · 2015 · Background
    PubMed: PMID 25598004 · NCT04544280 · Muscle Spasticity
  7. Migraine: multiple processes, complex pathophysiology.
    Burstein R, Noseda R, Borsook D, et al. · J Neurosci · 2015 · Background
    PubMed: PMID 25926442 · NCT05598723

2014 (15 papers)

  1. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
    Wang L, Sun Y, Yang W, et al. · Toxicon · 2014 · Trial result
    PubMed: PMID 24560879 · NCT03758235 · Urinary Incontinence
  2. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R, Harding C, Teo L, et al. · Int J Urol · 2014 · Trial result
    PubMed: PMID 23819724 · NCT03758235 · Urinary Incontinence
  3. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
    Veenboer PW, Bosch JL · J Urol · 2014 · Trial result
    PubMed: PMID 24140548 · NCT03758235 · Urinary Incontinence
  4. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD, Gollomp SM, Jankovic J, et al. · J Neural Transm (Vienna) · 2014 · Trial result
    PubMed: PMID 23435927 · NCT00406367 · Blepharospasm
  5. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
    Evidente VG, Fernandez HH, LeDoux MS, et al. · J Neural Transm (Vienna) · 2014 · Trial result
    PubMed: PMID 23779062 · NCT00407030 · Torticollis
  6. Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial.
    Campanati A, Giuliodori K, Martina E, et al. · J Neural Transm (Vienna) · 2014 · Trial result
    PubMed: PMID 24052109 · NCT03758235 · Urinary Incontinence
  7. Post-traumatic headaches in civilians and military personnel: a comparative, clinical review.
    Theeler B, Lucas S, Riechers RG, et al. · Headache · 2014 · Background
    PubMed: PMID 23721236 · NCT07267819 · Brain Injuries, Traumatic
  8. Chronic migraine.
    Schwedt TJ · BMJ · 2014 · Background
    PubMed: PMID 24662044 · NCT05598723
  9. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.
    Rendas-Baum R, Bloudek LM, Maglinte GA, et al. · Qual Life Res · 2014 · Background
    PubMed: PMID 22797868 · NCT05598723
  10. Triptans for symptomatic treatment of migraine headache.
    Pringsheim T, Becker WJ · BMJ · 2014 · Background
    PubMed: PMID 24711666 · NCT07267819 · Brain Injuries, Traumatic
  11. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.
    Mols F, Beijers T, Vreugdenhil G, et al. · Support Care Cancer · 2014 · Background
    PubMed: PMID 24789421 · NCT03571334
  12. A prospective study of prevalence and characterization of headache following mild traumatic brain injury.
    Lucas S, Hoffman JM, Bell KR, et al. · Cephalalgia · 2014 · Background
    PubMed: PMID 23921798 · NCT07267819 · Brain Injuries, Traumatic
  13. The International Classification of Headache Disorders, 3rd edition (beta version).
    Headache Classification Committee of the International Headache Society (IHS) · Cephalalgia · 2014 · Background
    PubMed: PMID 23771276 · NCT05598723
  14. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy.
    Ghasemi M, Ansari M, Basiri K, et al. · J Res Med Sci · 2014 · Background
    PubMed: PMID 24778662 · NCT03571334
  15. Relationship between massive chronic rotator cuff tear pattern and loss of active shoulder range of motion.
    Collin P, Matsumura N, Lädermann A, et al. · J Shoulder Elbow Surg · 2014 · Background
    PubMed: PMID 24433628 · NCT05327972 (DEROTOX)

2013 (8 papers)

  1. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B, Flynn TC, Schlöbe A, et al. · Dermatol Surg · 2013 · Trial result
    PubMed: PMID 23190342 · NCT00512135
  2. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A, Carruthers J, Coleman WP, et al. · Dermatol Surg · 2013 · Trial result
    PubMed: PMID 23379292 · NCT00770029
  3. Population-based consultation patterns in patients with shoulder pain diagnoses.
    Tekavec E, Jöud A, Rittner R, et al. · BMC Musculoskelet Disord · 2013 · Background
    PubMed: PMID 23190941 · NCT05327972 (DEROTOX)
  4. The reasons why stroke patients expend so much energy to walk slowly.
    Stoquart G, Detrembleur C, Lejeune TM, et al. · Gait Posture · 2013 · Background
    PubMed: PMID 22555062 · NCT04544280 · Muscle Spasticity
  5. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
    Mohee A, Khan A, Harris N, et al. · BJU Int · 2013 · Background
    PubMed: PMID 22672569 · NCT03758235 · Urinary Incontinence
  6. Patterns of musculoskeletal pain in the population: a latent class analysis using a nationally representative interviewer-based survey of 4817 Danes.
    Hartvigsen J, Davidsen M, Hestbaek L, et al. · Eur J Pain · 2013 · Background
    PubMed: PMID 23042697 · NCT05327972 (DEROTOX)
  7. Treatment outcomes of chronic post-traumatic headaches after mild head trauma in US soldiers: an observational study.
    Erickson JC · Headache · 2013 · Background
    PubMed: PMID 21592097 · NCT07267819 · Brain Injuries, Traumatic
  8. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy.
    Chen WT, Yuan RY, Chiang SC, et al. · Clin J Pain · 2013 · Background
    PubMed: PMID 23462284 · NCT03571334

2012 (12 papers)

  1. Anti-apoptotic activity of hemagglutinin-33 and botulinum neurotoxin and its implications to therapeutic and countermeasure issues.
    Kumar R, Zhou Y, Ghosal K, et al. · Biochem Biophys Res Commun · 2012 · Trial result
    PubMed: PMID 22182409 · NCT03758235 · Urinary Incontinence
  2. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J, Comella C, Hanschmann A, et al. · Mov Disord · 2012 · Trial result
    PubMed: PMID 21520284 · NCT00406367 · Blepharospasm
  3. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL, Jankovic J, Truong DD, et al. · J Neurol Sci · 2012 · Trial result
    PubMed: PMID 21764407 · NCT00407030 · Torticollis
  4. Clinical relevance of botulinum toxin immunogenicity.
    Benecke R · BioDrugs · 2012 · Trial result
    PubMed: PMID 22385408 · NCT03758235 · Urinary Incontinence
  5. Costs of shoulder pain and resource use in primary health care: a cost-of-illness study in Sweden.
    Virta L, Joranger P, Brox JI, et al. · BMC Musculoskelet Disord · 2012 · Background
    PubMed: PMID 22325050 · NCT05327972 (DEROTOX)
  6. Hypoxia: a critical regulator of early human tendinopathy.
    Millar NL, Reilly JH, Kerr SC, et al. · Ann Rheum Dis · 2012 · Background
    PubMed: PMID 21972243 · NCT05327972 (DEROTOX)
  7. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.
    Kottschade LA, Sloan JA, Mazurczak MA, et al. · Support Care Cancer · 2012 · Background
    PubMed: PMID 20936417 · NCT03571334
  8. Do botulinum toxins have a role in the management of neuropathic pain?: a focused review.
    Francisco GE, Tan H, Green M, et al. · Am J Phys Med Rehabil · 2012 · Background
    PubMed: PMID 22660369 · NCT03571334
  9. Validated assessment scales for the upper face.
    Flynn TC, Carruthers A, Carruthers J, et al. · Dermatol Surg · 2012 · Background
    PubMed: PMID 22316187 · NCT02122536
  10. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
    Bagley CL, Rendas-Baum R, Maglinte GA, et al. · Headache · 2012 · Background
    PubMed: PMID 21929662 · NCT05598723
  11. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
    Argyriou AA, Bruna J, Marmiroli P, et al. · Crit Rev Oncol Hematol · 2012 · Background
    PubMed: PMID 21908200 · NCT03571334
  12. Measures of adult shoulder function: Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH) and its short version (QuickDASH), Shoulder Pain and Disability Index (SPADI), American Shoulder and Elbow Surgeons (ASES) Society standardized shoulder assessment form, Constant (Murley) Score (CS), Simple Shoulder Test (SST), Oxford Shoulder Score (OSS), Shoulder Disability Questionnaire (SDQ), and Western Ontario Shoulder Instability Index (WOSI).
    Angst F, Schwyzer HK, Aeschlimann A, et al. · Arthritis Care Res (Hoboken) · 2012 · Background
    PubMed: PMID 22588743 · NCT05327972 (DEROTOX)

2011 (5 papers)

  1. EAU guidelines on urinary incontinence.
    Thüroff JW, Abrams P, Andersson KE, et al. · Eur Urol · 2011 · Trial result
    PubMed: PMID 21130559 · NCT03758235 · Urinary Incontinence
  2. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
    Sattler G, Callander MJ, Grablowitz D, et al. · Dermatol Surg · 2011 · Trial result
    PubMed: PMID 21134045 · NCT00777803 (Head2Head)
  3. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Neumeister MW · J Hand Surg Am · 2011 · Background
    PubMed: PMID 21134617 · NCT03571334
  4. The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
    Lavoie Smith EM, Cohen JA, Pett MA, et al. · Oncol Nurs Forum · 2011 · Background
    PubMed: PMID 21356652 · NCT03571334
  5. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
    Frevert J, Dressler D · Biologics · 2011 · Background
    PubMed: PMID 21209727 · NCT05598723

2010 (6 papers)

  1. Bladder afferent signaling: recent findings.
    Kanai A, Andersson KE · J Urol · 2010 · Trial result
    PubMed: PMID 20171668 · NCT03758235 · Urinary Incontinence
  2. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
    Haylen BT, de Ridder D, Freeman RM, et al. · Neurourol Urodyn · 2010 · Trial result
    PubMed: PMID 19941278 · NCT03758235 · Urinary Incontinence
  3. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, et al. · Cephalalgia · 2010 · Background
    PubMed: PMID 20647171 · NCT05598723
  4. Tendinopathy and tears of the rotator cuff are associated with hypoxia and apoptosis.
    Benson RT, McDonnell SM, Knowles HJ, et al. · J Bone Joint Surg Br · 2010 · Background
    PubMed: PMID 20190320 · NCT05327972 (DEROTOX)
  5. Clinical practice guidelines for the surgical management of rotator cuff tears in adults.
    Beaudreuil J, Dhénain M, Coudane H, et al. · Orthop Traumatol Surg Res · 2010 · Background
    PubMed: PMID 20464793 · NCT05327972 (DEROTOX)
  6. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, et al. · Cephalalgia · 2010 · Background
    PubMed: PMID 20647170 · NCT05598723

2009 (6 papers)

  1. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.
    Yuan RY, Sheu JJ, Yu JM, et al. · Neurology · 2009 · Background
    PubMed: PMID 19246421 · NCT03571334
  2. Sickness absence for upper limb disorders in a French company.
    Wilson d'Almeida K, Godard C, Leclerc A, et al. · Occup Med (Lond) · 2009 · Background
    PubMed: PMID 18587147 · NCT05327972 (DEROTOX)
  3. Development and preliminary validation of the NePIQoL: a quality-of-life measure for neuropathic pain.
    Poole HM, Murphy P, Nurmikko TJ, et al. · J Pain Symptom Manage · 2009 · Background
    PubMed: PMID 18676118 · NCT03571334
  4. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
    Park SB, Krishnan AV, Lin CS, et al. · Curr Med Chem · 2009 · Background
    PubMed: PMID 19075655 · NCT03571334
  5. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
    Favre-Guilmard C, Auguet M, Chabrier PE, et al. · Eur J Pharmacol · 2009 · Background
    PubMed: PMID 19576881 · NCT03571334
  6. Botulinum toxin for neuropathic pain?
    Apfel SC · Neurology · 2009 · Background
    PubMed: PMID 19321845 · NCT03571334

2008 (4 papers)

  1. Validation of the erection hardness score.
    Mulhall JP, Goldstein I, Bushmakin AG, et al. · J Sex Med · 2008 · Background
    PubMed: PMID 17888069 · NCT05196308 (MENOX) · Erectile Dysfunction
  2. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
    Lucioni A, Bales GT, Lotan TL, et al. · BJU Int · 2008 · Background
    PubMed: PMID 18184328 · NCT03571334
  3. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait.
    Caty GD, Detrembleur C, Bleyenheuft C, et al. · Stroke · 2008 · Background
    PubMed: PMID 18635841 · NCT04544280 · Muscle Spasticity
  4. Botulinum toxin products overview.
    Carruthers A, Carruthers J · Skin Therapy Lett · 2008 · Background
    PubMed: PMID 18806905 · NCT05598723

2007 (4 papers)

  1. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
    Jost WH, Blümel J, Grafe S, et al. · Drugs · 2007 · Trial result
    PubMed: PMID 17385940 · NCT03758235 · Urinary Incontinence
  2. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
    Rao RD, Michalak JC, Sloan JA, et al. · Cancer · 2007 · Background
    PubMed: PMID 17853395 · NCT03571334
  3. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study.
    Placzek R, Drescher W, Deuretzbacher G, et al. · J Bone Joint Surg Am · 2007 · Background
    PubMed: PMID 17272437 · NCT05327972 (DEROTOX)
  4. Validation of the eleven-point pain scale in the measurement of migraine headache pain.
    Kwong WJ, Pathak DS · Cephalalgia · 2007 · Background
    PubMed: PMID 17376110 · NCT05598723

2006 (4 papers)

  1. Epidemiologic surveillance of upper-extremity musculoskeletal disorders in the working population.
    Roquelaure Y, Ha C, Leclerc A, et al. · Arthritis Rheum · 2006 · Background
    PubMed: PMID 17013824 · NCT05327972 (DEROTOX)
  2. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain.
    Park HJ, Lee Y, Lee J, et al. · Can J Anaesth · 2006 · Background
    PubMed: PMID 16636031 · NCT03571334
  3. Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral.
    Linsell L, Dawson J, Zondervan K, et al. · Rheumatology (Oxford) · 2006 · Background
    PubMed: PMID 16263781 · NCT05327972 (DEROTOX)
  4. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial.
    Jensen MP, Friedman M, Bonzo D, et al. · Clin J Pain · 2006 · Background
    PubMed: PMID 16340598 · NCT03571334

2005 (5 papers)

  1. Headache after moderate and severe traumatic brain injury: a longitudinal analysis.
    Walker WC, Seel RT, Curtiss G, et al. · Arch Phys Med Rehabil · 2005 · Background
    PubMed: PMID 16181945 · NCT07267819 · Brain Injuries, Traumatic
  2. Shoulder disorders: a state-of-the-art review.
    van der Heijden GJ · Baillieres Best Pract Res Clin Rheumatol · 2005 · Background
    PubMed: PMID 10952865 · NCT05327972 (DEROTOX)
  3. Diagnosis and relation to general health of shoulder disorders presenting to primary care.
    Ostör AJ, Richards CA, Prevost AT, et al. · Rheumatology (Oxford) · 2005 · Background
    PubMed: PMID 15769790 · NCT05327972 (DEROTOX)
  4. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).
    Bouhassira D, Attal N, Alchaar H, et al. · Pain · 2005 · Background
    PubMed: PMID 15733628 · NCT03571334
  5. Incidence and prevalence of complaints of the neck and upper extremity in general practice.
    Bot SD, van der Waal JM, Terwee CB, et al. · Ann Rheum Dis · 2005 · Background
    PubMed: PMID 15608309 · NCT05327972 (DEROTOX)

2004 (4 papers)

  1. Safety of botulinum toxin type A: a systematic review and meta-analysis.
    Naumann M, Jankovic J · Curr Med Res Opin · 2004 · Background
    PubMed: PMID 15265242 · NCT05598723
  2. Prevalence and incidence of shoulder pain in the general population; a systematic review.
    Luime JJ, Koes BW, Hendriksen IJ, et al. · Scand J Rheumatol · 2004 · Background
    PubMed: PMID 15163107 · NCT05327972 (DEROTOX)
  3. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.
    Cui M, Khanijou S, Rubino J, et al. · Pain · 2004 · Background
    PubMed: PMID 14715398 · NCT03571334
  4. Postural stability in the elderly: empirical confirmation of a theoretical model.
    Corriveau H, Hébert R, Raîche M, et al. · Arch Gerontol Geriatr · 2004 · Background
    PubMed: PMID 15249153 · NCT04544280 · Muscle Spasticity

2003 (1 paper)

  1. Urinary symptoms in Parkinson's disease: prevalence and associated factors.
    Campos-Sousa RN, Quagliato E, da Silva BB, et al. · Arq Neuropsiquiatr · 2003 · Trial result
    PubMed: PMID 12894267 · NCT03758235 · Urinary Incontinence

2002 (1 paper)

  1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
    Abrams P, Cardozo L, Fall M, et al. · Neurourol Urodyn · 2002 · Trial result
    PubMed: PMID 11857671 · NCT03758235 · Urinary Incontinence

2001 (3 papers)

  1. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
    Di Stasi SM, Giannantoni A, Vespasiani G, et al. · J Urol · 2001 · Trial result
    PubMed: PMID 11176403 · NCT03758235 · Urinary Incontinence
  2. Natural history of asymptomatic rotator cuff tears: a longitudinal analysis of asymptomatic tears detected sonographically.
    Yamaguchi K, Tetro AM, Blam O, et al. · J Shoulder Elbow Surg · 2001 · Background
    PubMed: PMID 11408898 · NCT05327972 (DEROTOX)
  3. Development of a shoulder pain and disability index.
    Roach KE, Budiman-Mak E, Songsiridej N, et al. · Arthritis Care Res · 2001 · Background
    PubMed: PMID 11188601 · NCT05327972 (DEROTOX)

2000 (2 papers)

  1. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease.
    Lemack GE, Dewey RB, Roehrborn CG, et al. · Urology · 2000 · Trial result
    PubMed: PMID 10925088 · NCT03758235 · Urinary Incontinence
  2. Mobility difficulties and physical activity as predictors of mortality and loss of independence in the community-living older population.
    Hirvensalo M, Rantanen T, Heikkinen E, et al. · J Am Geriatr Soc · 2000 · Background
    PubMed: PMID 10811541 · NCT04544280 · Muscle Spasticity

1999 (1 paper)

  1. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
    Kessler KR, Skutta M, Benecke R, et al. · J Neurol · 1999 · Background
    PubMed: PMID 10367694 · NCT05598723

1998 (1 paper)

  1. Self-assessment of general health status in patients with five common shoulder conditions.
    Gartsman GM, Brinker MR, Khan M, et al. · J Shoulder Elbow Surg · 1998 · Background
    PubMed: PMID 9658347 · NCT05327972 (DEROTOX)

1997 (1 paper)

  1. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale.
    Galer BS, Jensen MP · Neurology · 1997 · Background
    PubMed: PMID 9040716 · NCT03571334

1996 (1 paper)

  1. Shoulder disorders in general practice: incidence, patient characteristics, and management.
    van der Windt DA, Koes BW, de Jong BA, et al. · Ann Rheum Dis · 1996 · Background
    PubMed: PMID 8546527 · NCT05327972 (DEROTOX)

1995 (2 papers)

  1. Translation of the glenohumeral joint with simulated active elevation.
    Wuelker N, Schmotzer H, Thren K, et al. · Clin Orthop Relat Res · 1995 · Background
    PubMed: PMID 7994959 · NCT05327972 (DEROTOX)
  2. Shoulder pain in a community-based rheumatology clinic.
    Vecchio P, Kavanagh R, Hazleman BL, et al. · Br J Rheumatol · 1995 · Background
    PubMed: PMID 7788173 · NCT05327972 (DEROTOX)

1994 (2 papers)

  1. Musculoskeletal clinic in general practice: study of one year's referrals.
    Peters D, Davies P, Pietroni P, et al. · Br J Gen Pract · 1994 · Background
    PubMed: PMID 8312034 · NCT05327972 (DEROTOX)
  2. Temporal, kinematic, and kinetic variables related to gait speed in subjects with hemiplegia: a regression approach.
    Olney SJ, Griffin MP, McBride ID, et al. · Phys Ther · 1994 · Background
    PubMed: PMID 8066114 · NCT04544280 · Muscle Spasticity

1992 (1 paper)

  1. Changing profile of joint disorders with age: findings from a postal survey of the population of Calderdale, West Yorkshire, United Kingdom.
    Badley EM, Tennant A · Ann Rheum Dis · 1992 · Background
    PubMed: PMID 1533506 · NCT05327972 (DEROTOX)

1988 (1 paper)

  1. Gait changes in adult onset hemiplegia.
    Pinzur MS, Sherman R, DiMonte-Levine P, et al. · Am J Phys Med · 1988 · Background
    PubMed: PMID 3324770 · NCT04544280 · Muscle Spasticity

1986 (1 paper)

  1. Late-life migraine accompaniments--further experience.
    Fisher CM · Stroke · 1986 · Background
    PubMed: PMID 3532432 · NCT05598723

1984 (1 paper)

  1. Hemiplegic gait: analysis of temporal variables.
    Brandstater ME, de Bruin H, Gowland C, et al. · Arch Phys Med Rehabil · 1984 · Background
    PubMed: PMID 6661021 · NCT04544280 · Muscle Spasticity

1983 (1 paper)

  1. Delineation of diagnostic criteria and a rehabilitation program for rotator cuff injuries.
    Jobe FW, Moynes DR · Am J Sports Med · 1983 · Background
    PubMed: PMID 7180952 · NCT05327972 (DEROTOX)

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).